Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04191629
Other study ID # VSH01
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date May 4, 2016
Est. completion date February 28, 2021

Study information

Verified date December 2019
Source Asociación para Evitar la Ceguera en México
Contact Valeria Sanchez-Huerta, MD
Phone +5210841400
Email valeriash@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Single center, phase 1 study to evaluate the safety and tolerability of EO1404 in subjects with corneal edema secondary to pseudophakic bullous keratopathy or Fuch's endothelial dystrophy.


Recruitment information / eligibility

Status Recruiting
Enrollment 35
Est. completion date February 28, 2021
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria:

1. Age = 21 years

2. Pseudophakic with a posterior chamber intraocular lens.

3. Symptomatic corneal edema associated with endothelial dysfunction which may be secondary to Fuchs corneal dystrophy or pseudophakic bullous keratopathy.

a Symptoms including reduced vision and/or glare, and/or pain; subject may or may not have been on topical therapies such as 5% sodium chloride drops or prednisolone acetate 1% drops.

b ETDRS-best corrected visual acuity worse than 20/63 on Snellen. c Central corneal thickness < 2 mm by ultrasound pachymetry or OCT. d Subject must have progressed far enough in their clinical course to be considered a surgical candidate for full-thickness corneal transplantation or endothelial keratoplasty.

4. Subject must understand and sign the informed consent. If the subject's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the subject in their maternal language.

5. Subject must be medically able and willing to undergo the protocol-required procedures.

Exclusion Criteria:

All ocular criteria apply to study eye unless otherwise noted.

1. Other corneal disease, including active or prior herpetic ocular infection; active inflammation; corneal scarring from trauma, burns, or infection; or band keratopathy.

2. Visual acuity in the fellow eye is worse than 20/200.

3. Anterior chamber intraocular lens.

4. Subject requires topical, intravenous or oral acyclovir and/or related products during study duration

5. History of vitrectomy.

6. History of refractive surgery.

7. Macular disease that in the investigator and/or sponsor's opinion would limit the ability of the subject to demonstrate improvement in BCVA.

8. Prior incisional eye surgery within 3 months prior to study treatment.

9. Subject is receiving systemic steroids or other systemic immunosuppressive medications.

10. Subject is currently participating in or has participated within the last 3 months in any other clinical trial of an investigational drug by ocular or systemic administration.

11. History of uveitis or other ocular inflammatory disease.

12. History of glaucoma, or peripheral anterior synechiae on gonioscopy.

13. History of incisional glaucoma surgery (e.g., trabeculectomy, glaucoma drainage implant).

14. Female subject who is pregnant, nursing, or planning to become pregnant, or who is of childbearing potential and not using a reliable means of contraception during the study.

15. Subject is immunodeficient, or tested positive for HIV.

16. Subject is on chemotherapy.

17. History of malignancy other than basal cell carcinoma, UNLESS the malignancy was treated successfully 5 years prior to inclusion in the study.

18. History of ocular neoplasm.

Study Design


Intervention

Combination Product:
EO1404

Procedure:
Endothelial brushing or Descemet stripping


Locations

Country Name City State
Mexico Asociación Para Evitar la Ceguera en México, IAP, Hospital "Dr. Luis Sánchez Bulnes" Mexico City

Sponsors (2)

Lead Sponsor Collaborator
Valeria Sanchez-Huerta Emmecell

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of Adverse Events Evaluation of safety adverse events including worsening of corneal edema and increase in intraocular pressure 12 months
Secondary BVCA Best corrected visual acuity 12 months
Secondary Corneal thickness Decrease in corneal thickness 12 months
See also
  Status Clinical Trial Phase
Completed NCT03248037 - Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation Phase 3
Recruiting NCT03275896 - Evaluation of the Efficacy of Descemet Membrane Transplantation for the Treatment of Fuchs' Endothelial Dystrophy Early Phase 1
Completed NCT02332109 - ODM 5 in the Treatment of Corneal Edematous Fuchs' Endothelial Dystrophy N/A
Completed NCT02470793 - Technique And Results In Endothelial Keratoplasty N/A
Recruiting NCT01206127 - DSAEK- Postoperative Positioning and Transplant Dislocation N/A
Recruiting NCT03407755 - Air Versus SF6 for Descemet's Membrane Endothelial Keratoplasty (DMEK) N/A
Completed NCT04140422 - Eye Drops for Early Morning-Associated Corneal Swelling of the Cornea N/A
Recruiting NCT06048380 - The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery Phase 3
Completed NCT02793310 - DMEK Versus DSAEK Study N/A
Completed NCT01795001 - The Molecular Pathogenesis of Late-onset Fuchs' Endothelial Corneal Dystrophy
Completed NCT04057053 - Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty Early Phase 1
Terminated NCT01361282 - Using the Optovue OCT to Select IOL Power N/A
Completed NCT02542644 - Assessment of Corneal Graft Attachment in Patients With Fuchs Endothelial Corneal Dystrophy Following DMEK Using Ultra-high Resolution OCT N/A
Completed NCT05399095 - Supine Positioning for Graft Attachment After Descemet Membrane Endothelial Keratoplasty N/A
Completed NCT04752020 - Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty Early Phase 1
Not yet recruiting NCT05716945 - The OPTIMISE Study Phase 4
Recruiting NCT03575130 - Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy Phase 2
Recruiting NCT02118922 - A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
Completed NCT04420429 - The Effect Of Preoperative Parameters On Success After DMEK Surgery
Withdrawn NCT04018417 - Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections. Phase 2/Phase 3